Heart failure & cardiomyopathiesSecondary analysis
Impact of Age on Long-Term Clinical Outcomes Following HeartMate 3 Left Ventricular Assist Device (LVAD) Implantation
- Secondary analysis of the MOMENTUM 3 randomised trial
- age-stratified
Authors' conclusion
Age is associated with outcomes in HM3 patients, with younger individuals showing better survival and fewer bleeding events.
Study context
- Population
- HeartMate 3 LVAD recipients in the MOMENTUM 3 trial
- Participants
- 2,200 participants
- Comparison
- HM3 LVAD outcomes by age group
- Primary endpoint
- Survival and survival free of disabling stroke or reoperation
- Follow-up
- 2 years
Primary result
As reported in the abstract
2-year survival
Each group vs <50 yearsHazard ratio (95% CI)P value
50-59 yearssurvival
1.16(0.77–1.75)
P = 0.4760-69 yearssurvival
1.76(1.21–2.57)
P = 0.0033≥70 yearssurvival
2.24(1.50–3.34)
P < 0.0001≥70 yearssurvival free of disabling stroke or reoperation: 70.5% vs 82.3%
1.46(1.04–2.04)
P = 0.028Safety
| Outcome | <50 years | 50-59 years | 60-69 years | ≥70 years | P value |
|---|---|---|---|---|---|
| GI bleeding | 0.12 events per patient-year | Not reported in the abstract | Not reported in the abstract | 0.42 events per patient-year | P < 0.001 |
| Sepsis | 0.12 EPPY | Not reported in the abstract | Not reported in the abstract | 0.16 EPPY | P = 0.035 |
| Driveline infection · reduced in older | 0.29 EPPY | Not reported in the abstract | Not reported in the abstract | 0.12 EPPY | P < 0.001 |
| Hemorrhagic stroke | 0.045 EPPY | Not reported in the abstract | Not reported in the abstract | 0.028 EPPY | P = 0.027 |
Hemorrhagic stroke
- Stroke rates low overall
Original publication
Impact of Age on Long-Term Clinical Outcomes Following HeartMate 3 LVAD Implantation. JACC Heart Fail. Published 29 June 2026. doi:10.1016/j.jchf.2026.103183
Summarised from the published abstract; every number is checked against it